Free Trial

Evotec (EVO) Competitors

Evotec logo
$4.03 +0.02 (+0.50%)
Closing price 04:00 PM Eastern
Extended Trading
$4.02 -0.01 (-0.25%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EVO vs. TGTX, TLX, VRNA, LNTH, AXSM, GRFS, NUVL, ADMA, PCVX, and KRYS

Should you be buying Evotec stock or one of its competitors? The main competitors of Evotec include TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Verona Pharma (VRNA), Lantheus (LNTH), Axsome Therapeutics (AXSM), Grifols (GRFS), Nuvalent (NUVL), ADMA Biologics (ADMA), Vaxcyte (PCVX), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.

Evotec vs.

TG Therapeutics (NASDAQ:TGTX) and Evotec (NASDAQ:EVO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, community ranking, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

In the previous week, TG Therapeutics had 11 more articles in the media than Evotec. MarketBeat recorded 11 mentions for TG Therapeutics and 0 mentions for Evotec. TG Therapeutics' average media sentiment score of 1.55 beat Evotec's score of 1.16 indicating that TG Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
TG Therapeutics Very Positive
Evotec Positive

Evotec has a net margin of 0.00% compared to TG Therapeutics' net margin of -5.42%. Evotec's return on equity of 0.00% beat TG Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TG Therapeutics-5.42% -8.32% -3.40%
Evotec N/A N/A N/A

TG Therapeutics currently has a consensus target price of $40.80, suggesting a potential upside of 19.16%. Evotec has a consensus target price of $5.93, suggesting a potential upside of 47.23%. Given Evotec's higher probable upside, analysts plainly believe Evotec is more favorable than TG Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TG Therapeutics
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Evotec
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40

TG Therapeutics has higher earnings, but lower revenue than Evotec.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TG Therapeutics$386.39M14.07$12.67M$0.24142.67
Evotec$788.22M1.82-$90.82MN/AN/A

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by insiders. Comparatively, 1.0% of Evotec shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

TG Therapeutics received 652 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 76.27% of users gave TG Therapeutics an outperform vote while only 53.85% of users gave Evotec an outperform vote.

CompanyUnderperformOutperform
TG TherapeuticsOutperform Votes
659
76.27%
Underperform Votes
205
23.73%
EvotecOutperform Votes
7
53.85%
Underperform Votes
6
46.15%

TG Therapeutics has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500.

Summary

TG Therapeutics beats Evotec on 11 of the 16 factors compared between the two stocks.

Get Evotec News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVO vs. The Competition

MetricEvotecPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.43B$6.49B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E RatioN/A9.1826.8919.71
Price / Sales1.82252.26386.75120.59
Price / Cash161.0865.8538.2534.62
Price / Book1.186.456.774.50
Net Income-$90.82M$144.21M$3.23B$248.22M
7 Day Performance2.28%2.46%1.82%0.56%
1 Month Performance1.51%4.59%11.12%13.17%
1 Year Performance-22.05%-2.68%17.09%7.30%

Evotec Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVO
Evotec
1.4949 of 5 stars
$4.03
+0.5%
$5.93
+47.2%
-21.2%$1.43B$788.22M0.004,200Positive News
Gap Down
TGTX
TG Therapeutics
3.8069 of 5 stars
$34.99
+4.0%
$40.80
+16.6%
+106.0%$5.56B$386.39M-349.87290Positive News
TLX
Telix Pharmaceuticals Limited American Depositary Shares
N/A$16.25
-5.4%
$22.00
+35.4%
N/A$5.49B$783.21M0.00N/A
VRNA
Verona Pharma
2.6573 of 5 stars
$67.53
+6.6%
$81.50
+20.7%
+492.7%$5.48B$118.54M-35.1730Positive News
Gap Down
LNTH
Lantheus
4.4483 of 5 stars
$79.52
-2.7%
$132.67
+66.8%
-6.9%$5.45B$1.54B13.23700Positive News
High Trading Volume
AXSM
Axsome Therapeutics
4.7164 of 5 stars
$110.16
+2.2%
$172.14
+56.3%
+35.4%$5.42B$432.16M-18.39380Positive News
Analyst Forecast
Insider Trade
GRFS
Grifols
3.1487 of 5 stars
$7.73
+8.9%
N/A+6.8%$5.31B$7.21B6.6126,300News Coverage
Positive News
NUVL
Nuvalent
2.4709 of 5 stars
$73.63
+5.4%
$115.50
+56.9%
+5.6%$5.27BN/A-21.2240News Coverage
Positive News
ADMA
ADMA Biologics
3.1804 of 5 stars
$20.45
+2.4%
$24.25
+18.6%
+109.6%$4.86B$459.38M73.04530News Coverage
Positive News
PCVX
Vaxcyte
3.0946 of 5 stars
$31.59
+1.4%
$136.50
+332.1%
-53.9%$4.08BN/A-6.87160Positive News
KRYS
Krystal Biotech
4.9053 of 5 stars
$139.43
+5.5%
$218.63
+56.8%
-24.1%$4.03B$333.45M46.63210Positive News

Related Companies and Tools


This page (NASDAQ:EVO) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners